Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verona Pharma Plc (VRNA)
NASDAQ:VRNA
VRNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.39 - $65.50
Previous CloseN/A
Volume658.49K
Average Volume (3M)1.49M
Market Cap
$5.25B
Enterprise Value$2.23B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Feb 27, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding81,831,170
10 Day Avg. Volume1,173,534
30 Day Avg. Volume1,491,451
Standard Deviation0.24
R-Squared0.00767
Alpha0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)930.93
Price to Cash Flow (P/CF)-20.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.29K
Enterprise Value/Ebitda-17.87
Forecast
1Y Price Target
$70.50Price Target Upside9.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceOhtuvayre's 4Q revenue of $36M was markedly higher than the estimate of $15.1M, demonstrating excitement for this new mechanism in COPD treatment.
Market PositionOhtuvayre's premium pricing strategy and receipt of a permanent J-code allow most patients to pay a low monthly copay, enhancing market accessibility.
Product LaunchThe strong launch of Ohtuvayre signals a strong future in the treatment of COPD, with its new dual mechanism being viewed as a game changer by physicians.
Bears Say
Long-term Pricing PressureThere is an anticipation of a 25% price cut in 2033 due to the Inflation Reduction Act and a 40% price cut in 2036 due to patent expiration.
Market CompetitionThe U.S. COPD market is large and crowded, with commercial success not guaranteed due to competition from established players like GSK and AstraZeneca.
Pricing ChallengesA 25% cut in pricing is modeled in 2033 due to the Inflation Reduction Act, and a 40% price cut in 2036 due to patent expiration.
---
Ownership Overview
42.79% Insiders
12.62% Mutual Funds
0.25% Other Institutional Investors
43.68% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRNA FAQ
What was Verona Pharma Plc’s price range in the past 12 months?
Verona Pharma Plc lowest stock price was $11.39 and its highest was $65.50 in the past 12 months.
What is Verona Pharma Plc’s market cap?
Verona Pharma Plc’s market cap is $5.25B.
When is Verona Pharma Plc’s upcoming earnings report date?
Verona Pharma Plc’s upcoming earnings report date is Feb 27, 2025 which is in 5 days.
How were Verona Pharma Plc’s earnings last quarter?
Verona Pharma Plc released its earnings results on Nov 04, 2024. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.068 by -$0.002.
Is Verona Pharma Plc overvalued?
According to Wall Street analysts Verona Pharma Plc’s price is currently Undervalued.
Does Verona Pharma Plc pay dividends?
Verona Pharma Plc does not currently pay dividends.
What is Verona Pharma Plc’s EPS estimate?
Verona Pharma Plc’s EPS estimate is -0.03.
How many shares outstanding does Verona Pharma Plc have?
Verona Pharma Plc has 81,831,170 shares outstanding.
What happened to Verona Pharma Plc’s price movement after its last earnings report?
Verona Pharma Plc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.068. Following the earnings report the stock price went up 9.062%.
Which hedge fund is a major shareholder of Verona Pharma Plc?
Currently, no hedge funds are holding shares in VRNA
---
Verona Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$70.50 (9.83% Upside)
$70.50 (9.83% Upside)
Blogger Sentiment
Neutral
VRNA Sentiment 50%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $88.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
277.58%
12-Months-Change
Fundamentals
Return on Equity
-78.35%
Trailing 12-Months
Asset Growth
30.55%
Trailing 12-Months
Company Description
Verona Pharma Plc
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
---
VRNA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong positive sentiment primarily due to the successful launch of Ohtuvayre, robust prescriber engagement, and the initiation of new clinical trials. Despite the increased expenses and significant net loss, the overall outlook remains positive with promising early sales and a solid financial position.Read More>---
VRNA Stock 12 Month Forecast
Average Price Target
$70.50
▲(9.83% Upside)
Technical Analysis
Best Analysts Covering VRNA
1 Year
1 Year Success Rate
15/17 ratings generated profit
1 Year Average Return
+134.46%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +134.46% per trade.
---